Has Joshua Barzilary, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,428 in general payments to Joshua Barzilary, MD across 16 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joshua Barzilary, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joshua Barzilary, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joshua Barzilary, MD

Endocrinology, Diabetes & Metabolism · Tucker, GANPI 1215045232

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Medtronic at 42.0% of the total. 2025 is the largest year on record at $823, 3.6 times the $232 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in GA, where the typical reported total is $2,873.

$1,428in general payments, 2019–2025

Across 16 payments — averaging $89.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$600
Bayer$415
Tandem Diabetes Care, Inc.$236
Radius Health, Inc.$122
Amgen$36
Dexcom, Inc.$19

$362,302in research payments, 2019–2025

Across 35 payments — averaging $10,351 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$289K
Bayer$34K
Astrazeneca UK Limited$28K
Vertex$11K

What the payments were for

Food & beverage$1,428100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	7	$600
Bayer	4	$415
Tandem Diabetes Care, Inc.	2	$236
Radius Health, Inc.	1	$122
Amgen	1	$36
Dexcom, Inc.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

MINIMED 780G$321
t:slim X2 Insulin Pump with Control-IQ$236
Kerendia$214
INPEN SMART INSULIN DELIVERY SYSTEM$136
Tymlos$122

How this compares

$1,428 in reported general payments places this provider in the 35th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024

$4,287

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	345	$256,285
JardianceEmpagliflozin	283	$98,724
Humulin R U-500 KwikpenInsulin Regular, Human	15	$40,848
MounjaroTirzepatide	34	$38,522
ForteoTeriparatide	24	$34,239
HumalogInsulin Lispro	188	$26,896
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7	23	$13,132
Insulin Glargine-Yfgn	113	$11,464
Humalog Kwikpen U-100Insulin Lispro	26	$7,238
Victoza 2-PakLiraglutide	11	$7,144
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm	56	$6,271
Humulin NInsulin Nph Human Isophane	28	$5,234
Testosterone	76	$4,762
Humulin RInsulin Regular, Human	47	$4,201
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm	18	$4,035

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Tucker

Bruce BodeAtlanta$1.5M
David RobertsonAtlanta$1.4M
Adeniyi OdugbesanLawrenceville$636K
Miguel MunozMarietta$476K
Jason BernerJasper$457K
Dawn Smiley-ByrdTaylorsville$385K
Barry JohnsMacon$335K
Jonathan OwnbyAtlanta$291K
Ismary DecastroSavannah$169K
Naland ShenoySnellville$139K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →